SI-BONE INC (SIBN)
US8257041090 - Common Stock
We assign a fundamental rating of 3 out of 10 to SIBN. SIBN was compared to 188 industry peers in the Health Care Equipment & Supplies industry. SIBN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SIBN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SIBN has reported negative net income.
In the past year SIBN has reported a negative cash flow from operations.
SIBN had negative earnings in each of the past 5 years.
In the past 5 years SIBN always reported negative operating cash flow.
1.2 Ratios
SIBN has a Return On Assets of -16.48%. This is comparable to the rest of the industry: SIBN outperforms 54.01% of its industry peers.
SIBN has a Return On Equity (-22.67%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -22.67% | ||
| ROIC | N/A |
ROA(3y)-29.14%
ROA(5y)-27.96%
ROE(3y)-43.35%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SIBN (77.70%) is better than 90.91% of its industry peers.
In the last couple of years the Gross Margin of SIBN has declined.
SIBN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 77.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.57%
GM growth 5Y-2.87%
2. Health
2.1 Basic Checks
SIBN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SIBN has been increased compared to 1 year ago.
Compared to 5 years ago, SIBN has more shares outstanding
Compared to 1 year ago, SIBN has an improved debt to assets ratio.
2.2 Solvency
SIBN has an Altman-Z score of 3.38. This indicates that SIBN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.38, SIBN is in the better half of the industry, outperforming 70.59% of the companies in the same industry.
A Debt/Equity ratio of 0.22 indicates that SIBN is not too dependend on debt financing.
The Debt to Equity ratio of SIBN (0.22) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.38 |
ROIC/WACCN/A
WACC8.99%
2.3 Liquidity
A Current Ratio of 8.25 indicates that SIBN has no problem at all paying its short term obligations.
SIBN has a Current ratio of 8.25. This is amongst the best in the industry. SIBN outperforms 88.77% of its industry peers.
SIBN has a Quick Ratio of 7.22. This indicates that SIBN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 7.22, SIBN belongs to the best of the industry, outperforming 89.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.25 | ||
| Quick Ratio | 7.22 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 22.69% over the past year.
Looking at the last year, SIBN shows a quite strong growth in Revenue. The Revenue has grown by 18.98% in the last year.
Measured over the past years, SIBN shows a very strong growth in Revenue. The Revenue has been growing by 20.18% on average per year.
EPS 1Y (TTM)22.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)18.98%
Revenue growth 3Y23.69%
Revenue growth 5Y20.18%
Sales Q2Q%18.6%
3.2 Future
Based on estimates for the next years, SIBN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.09% on average per year.
The Revenue is expected to grow by 18.41% on average over the next years. This is quite good.
EPS Next Y19.94%
EPS Next 2Y15.23%
EPS Next 3Y15.09%
EPS Next 5YN/A
Revenue Next Year21.04%
Revenue Next 2Y19.17%
Revenue Next 3Y18.41%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
SIBN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SIBN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SIBN's earnings are expected to grow with 15.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.23%
EPS Next 3Y15.09%
5. Dividend
5.1 Amount
SIBN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SI-BONE INC
NASDAQ:SIBN (11/21/2024, 8:00:02 PM)
After market: 12.29 0 (0%)12.29
+0.14 (+1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap515.44M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -22.67% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 77.7% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.25 | ||
| Quick Ratio | 7.22 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)22.69%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y19.94%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)18.98%
Revenue growth 3Y23.69%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y